Literature DB >> 26122630

Screening Mucopolysaccharidosis Type IX in Patients with Juvenile Idiopathic Arthritis.

Ertugrul Kiykim1, Kenan Barut2, Mehmet Serif Cansever3, Cigdem Aktuglu Zeybek4, Tanyel Zubarioglu4, Ahmet Aydin4, Ozgur Kasapcopur2.   

Abstract

Mucopolysaccharidosis is a group of lysosomal disorders of a deficiency of specific enzyme required for glycosaminoglycan degradation. Mucopolysaccharidosis type IX is the rarest form of mucopolysaccharidosis. To date, only four patients have been reported. The first reported patient had mild short stature and periarticular soft tissue masses; the other reported patients are clinically indistinguishable from juvenile idiopathic arthritis. In the present study, we screened mucopolysaccharidosis type IX among patients with juvenile idiopathic arthritis with hyaluronidase enzyme assay. One hundred and eight patients with JIA and 50 healthy age-matched control subjects were enrolled in the study. Among all patients, none had deficient hyaluronidase activity. Though serum Hyal-1 activity was significantly increased in JIA patients, compared with control subjects (p < 0.000), no correlation was found between CRP, ESR, and Hyal-1 activity (p = 0.187). In conclusion, the data reported in our study indicates that systemic metabolic investigation for hyaluronidase activity is not recommended in all patients with JIA.

Entities:  

Keywords:  Hyaluronidase deficiency; Juvenile idiopathic arthritis; Mucopolysaccharidosis type IX

Year:  2015        PMID: 26122630      PMCID: PMC5059191          DOI: 10.1007/8904_2015_467

Source DB:  PubMed          Journal:  JIMD Rep        ISSN: 2192-8304


  14 in total

1.  International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001.

Authors:  Ross E Petty; Taunton R Southwood; Prudence Manners; John Baum; David N Glass; Jose Goldenberg; Xiaohu He; Jose Maldonado-Cocco; Javier Orozco-Alcala; Anne-Marie Prieur; Maria E Suarez-Almazor; Patricia Woo
Journal:  J Rheumatol       Date:  2004-02       Impact factor: 4.666

2.  A modified colorimetric method for the estimation of N-acetylamino sugars.

Authors:  J L REISSIG; J L STORMINGER; L F LELOIR
Journal:  J Biol Chem       Date:  1955-12       Impact factor: 5.157

3.  Clinical and biochemical manifestations of hyaluronidase deficiency.

Authors:  M R Natowicz; M P Short; Y Wang; G R Dickersin; M C Gebhardt; D I Rosenthal; K B Sims; A E Rosenberg
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

Review 4.  The mucopolysaccharidoses: a clinical review and guide to management.

Authors:  J E Wraith
Journal:  Arch Dis Child       Date:  1995-03       Impact factor: 3.791

5.  Examination of synovial fluid and serum hyaluronidase activity as a joint marker in rheumatoid arthritis and osteoarthritis patients (by zymography).

Authors:  H Nagaya; T Ymagata; S Ymagata; K Iyoda; H Ito; Y Hasegawa; H Iwata
Journal:  Ann Rheum Dis       Date:  1999-03       Impact factor: 19.103

6.  Mutations in HYAL1, a member of a tandemly distributed multigene family encoding disparate hyaluronidase activities, cause a newly described lysosomal disorder, mucopolysaccharidosis IX.

Authors:  B Triggs-Raine; T J Salo; H Zhang; B A Wicklow; M R Natowicz
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-25       Impact factor: 11.205

7.  Human serum hyaluronidase: characterization of a clinical assay.

Authors:  M R Natowicz; Y Wang
Journal:  Clin Chim Acta       Date:  1996-02-09       Impact factor: 3.786

8.  A mouse model of human mucopolysaccharidosis IX exhibits osteoarthritis.

Authors:  Dianna C Martin; Vasantha Atmuri; Richard J Hemming; Judith Farley; John S Mort; Sharon Byers; Sabine Hombach-Klonisch; Antonei B Csoka; Robert Stern; Barbara L Triggs-Raine
Journal:  Hum Mol Genet       Date:  2008-03-15       Impact factor: 6.150

9.  Skeletal and hematological anomalies in HYAL2-deficient mice: a second type of mucopolysaccharidosis IX?

Authors:  Laurence Jadin; Xiaoli Wu; Hao Ding; Gregory I Frost; Cécile Onclinx; Barbara Triggs-Raine; Bruno Flamion
Journal:  FASEB J       Date:  2008-09-04       Impact factor: 5.191

10.  Serum hyaluronidase aberrations in metabolic and morphogenetic disorders.

Authors:  Berta Fiszer-Szafarz; Barbara Czartoryska; Anna Tylki-Szymanska
Journal:  Glycoconj J       Date:  2005-11       Impact factor: 3.009

View more
  6 in total

Review 1.  Misdiagnosis in mucopolysaccharidoses.

Authors:  Karolina Wiśniewska; Jakub Wolski; Lidia Gaffke; Zuzanna Cyske; Karolina Pierzynowska; Grzegorz Węgrzyn
Journal:  J Appl Genet       Date:  2022-05-13       Impact factor: 2.653

Review 2.  Epidemiology of Mucopolysaccharidoses Update.

Authors:  Betul Çelik; Saori C Tomatsu; Shunji Tomatsu; Shaukat A Khan
Journal:  Diagnostics (Basel)       Date:  2021-02-10

3.  Epidemiology of mucopolysaccharidoses (MPS) in United States: challenges and opportunities.

Authors:  Yana Puckett; Alejandra Mallorga-Hernández; Adriana M Montaño
Journal:  Orphanet J Rare Dis       Date:  2021-05-29       Impact factor: 4.123

Review 4.  Sleep Disorders in Childhood Neurogenetic Disorders.

Authors:  Laura Beth Mann Dosier; Bradley V Vaughn; Zheng Fan
Journal:  Children (Basel)       Date:  2017-09-12

Review 5.  Diagnosis of Mucopolysaccharidoses.

Authors:  Francyne Kubaski; Fabiano de Oliveira Poswar; Kristiane Michelin-Tirelli; Maira Graeff Burin; Diana Rojas-Málaga; Ana Carolina Brusius-Facchin; Sandra Leistner-Segal; Roberto Giugliani
Journal:  Diagnostics (Basel)       Date:  2020-03-22

6.  Estimated prevalence of mucopolysaccharidoses from population-based exomes and genomes.

Authors:  Pâmella Borges; Gabriela Pasqualim; Roberto Giugliani; Filippo Vairo; Ursula Matte
Journal:  Orphanet J Rare Dis       Date:  2020-11-18       Impact factor: 4.123

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.